Achilles Therapeutics plc

NasdaqGS:ACHL Stock Report

Market Cap: US$32.1m

Achilles Therapeutics Future Growth

Future criteria checks 0/6

Achilles Therapeutics's earnings are forecast to decline at 18.5% per annum. EPS is expected to decline by 19.2% per annum.

Key information

-18.5%

Earnings growth rate

-19.2%

EPS growth rate

Biotechs earnings growth23.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated04 Apr 2024

Recent future growth updates

Recent updates

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 13
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Jul 19
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Mar 11
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 18
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles-led group gets €4M funding for personalized cell therapy manufacturing

Jul 21

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Apr 13
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Dec 27
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Earnings and Revenue Growth Forecasts

NasdaqGS:ACHL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-118-101N/A1
12/31/2025N/A-88-75N/A1
12/31/2024N/A-80-68N/A1
12/31/2023N/A-70-50-48N/A
9/30/2023N/A-75-57-54N/A
6/30/2023N/A-71-63-58N/A
3/31/2023N/A-71-63-57N/A
12/31/2022N/A-71-67-60N/A
9/30/2022N/A-65-62-54N/A
6/30/2022N/A-66-67-60N/A
3/31/2022N/A-65-70-63N/A
12/31/2021N/A-61-67-59N/A
9/30/2021N/A-56-65-53N/A
6/30/2021N/A-51-66-51N/A
3/31/2021N/A-42-50-36N/A
12/31/2020N/A-33-37-25N/A
9/30/2020N/A-25-29-22N/A
6/30/2020N/A-19-21-19N/A
3/31/2020N/A-16-20-18N/A
12/31/2019N/A-14-15-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACHL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACHL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACHL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ACHL's revenue is forecast to grow faster than the US market.

High Growth Revenue: ACHL is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACHL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.